{"id":8081,"date":"2025-10-10T17:47:22","date_gmt":"2025-10-10T17:47:22","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8081"},"modified":"2025-10-10T17:47:22","modified_gmt":"2025-10-10T17:47:22","slug":"jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","title":{"rendered":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases<\/em><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 billion as of Thursday\u2019s close. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the heart of the prospective deal is <strong>icotrokinra<\/strong>, a once-daily oral therapy targeting various immune-mediated conditions such as plaque psoriasis and ulcerative colitis. Under the existing agreement, J&amp;J holds exclusive commercialization rights to the drug. The two firms have been collaborating on development, and the acquisition would effectively give J&amp;J full control over a promising pipeline asset.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The strategic rationale for J&amp;J appears compelling. Its flagship immune-disease drug <strong>Stelara<\/strong> is facing increasing pressure from biosimilars and competitors, putting strain on long-term growth in immunology.  The potential acquisition therefore offers a pathway to replenish and strengthen its next-generation therapeutics portfolio.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Protagonist declined to comment on the acquisition talks, and J&amp;J did not immediately respond to requests for comment. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If completed, the deal would mirror a broader trend among major pharmaceutical players seeking to bolster their pipelines via biotech takeovers. For J&amp;J, securing full ownership of icotrokinra could accelerate its ambitions in oral immunology treatments and improve competitive footing in a fast-evolving market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/09\/kulr-technology-partners-with-soluna-to-launch-sustainable-bitcoin-mining-operations\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">KULR Technology Partners with Soluna to Launch Sustainable Bitcoin Mining Operations<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3001,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,361],"tags":[421,831,416,418,832,417],"coauthors":[454],"class_list":["post-8081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap","tag-growth","tag-jnj","tag-movers","tag-news","tag-ptgx","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T17:47:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1279\" \/>\n\t<meta property=\"og:image:height\" content=\"918\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline\",\"datePublished\":\"2025-10-10T17:47:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/\"},\"wordCount\":258,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/pexels-anna-nekrashevich-6801647.jpg\",\"keywords\":[\"Growth\",\"JNJ\",\"Movers\",\"News\",\"PTGX\",\"Stock Market\"],\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/\",\"name\":\"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/pexels-anna-nekrashevich-6801647.jpg\",\"datePublished\":\"2025-10-10T17:47:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/pexels-anna-nekrashevich-6801647.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/pexels-anna-nekrashevich-6801647.jpg\",\"width\":1279,\"height\":918,\"caption\":\"investing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/10\\\/10\\\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo","og_description":"Prospective acquisition of Protagonist Therapeutics centers on oral drug for immune diseases Johnson &amp; Johnson (JNJ) is reportedly in active talks to acquire Protagonist Therapeutics (PTGX), according to people familiar with the matter, a move that sent Protagonist\u2019s shares soaring more than 30 % during afternoon trading. The company\u2019s market value stood at about $4.2 [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","og_site_name":"Stoxpo","article_published_time":"2025-10-10T17:47:22+00:00","og_image":[{"width":1279,"height":918,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline","datePublished":"2025-10-10T17:47:22+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/"},"wordCount":258,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg","keywords":["Growth","JNJ","Movers","News","PTGX","Stock Market"],"articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/","name":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg","datePublished":"2025-10-10T17:47:22+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/05\/pexels-anna-nekrashevich-6801647.jpg","width":1279,"height":918,"caption":"investing"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/10\/10\/jj-eyes-biotech-buyout-to-strengthen-immunology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"J&amp;J Eyes Biotech Buyout to Strengthen Immunology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8081"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081\/revisions"}],"predecessor-version":[{"id":8082,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8081\/revisions\/8082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/3001"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8081"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}